Non-alcoholic fatty liver disease:understanding the role of aging, fatty acid transport and epigenetics by Sheedfar, Fareeba
  
 University of Groningen
Non-alcoholic fatty liver disease
Sheedfar, Fareeba
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Sheedfar, F. (2015). Non-alcoholic fatty liver disease: understanding the role of aging, fatty acid transport
and epigenetics. [S.l.]: [S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Role of CD36 in early NAFLD  
development varies with type of mice 
used as experimental control groups
Fareeba Sheedfar1, Eelke Brandsma1, Maaike Oosterveer2, Bastiaan Moesker3, 
Henk van der Molen1, Niels Kloosterhuis1, Jan Albert Kuivenhoven1, Alain de 
Bruin3, Bart van de Sluis1, Marten Hofker1, Debby Koonen1
1University of Groningen, University Medical Centre Groningen, Department of Pediatrics, Section Molecular Genetics, 
2Laboratory of Pediatrics and Laboratory Medicine, Groningen, The Netherlands; 3University of Southampton, Faculty of 
Medicine, Clinical and Experimental Sciences, Southampton General Hospital, Southampton, UK; 4Dutch Molecular Pathology 








Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver 
disease worldwide. Hepatic steatosis, the hallmark of NAFLD, is considered a benign 
and reversible process. However, it may progress to steatohepatitis (NASH) in the 
presence of inflammation. Since the underlying mechanisms that contribute to 
this transition are unclear, we examined the role of CD36, a long-chain fatty acid 
uptake protein, in the development and progression of NAFLD. We subjected 
CD36 wild type (WT), CD36 knockout (KO) and C57Bl/6 mice to a high-fat diet 
(HFD) for 12 weeks to induce NAFLD. The livers were dissected for biochemical 
and pathological assessment of NAFLD. Lipid accumulation was measured 
biochemically and gene expression was determined using qRT-PCR. Lack of 
CD36 increased hepatic steatosis in CD36 KO mice as compared with CD36 WT 
mice. This corresponded with a marked reduction in VLDL-TG secretion in CD36 
KO in comparison to CD36 WT mice. Moreover, ablation of CD36 did not affect 
the level of hepatic inflammation. In contrast, CD36 ablation was not associated 
with increased hepatic steatosis when using C57Bl/6 mice as controls. Although 
we observed a slight increase in hepatic inflammation when comparing CD36 
KO mice with C57Bl/6 mice, this was not significant. Thus, CD36 may protect 
against early NAFLD development, but only when using proper WT littermate 
controls. In addition, our data show that the type of mice used as experimental 
controls can explain most of the controversial findings in relation to CD36 and 
hepatic steatosis. Therefore, for a correct outcome, care should be taken in the 
experimental design and choice of controls. 
In hepatic steatosis, the balance 
between lipid uptake and lipid removal 
is disturbed (Cohen et al., 2011). Fatty 
acid uptake and lipid deposition in 
the liver are directly related to the 
expression of CD36, a transmembrane 
protein mediating long-chain fatty acid 
(LCFA) uptake across the cell membrane. 
CD36 has been shown to contribute 
to hepatic lipid accumulation in mice 
(Koonen et al., 2007a; Sheedfar et al., 
2014a) and in patients with steatosis 
(Miquilena-Colina et al., 2011; Sheedfar 
et al., 2014a). Genetic deficiency of 
Introduction
Driven by obesity, nonalcoholic 
fatty liver disease (NAFLD) is the 
hepatic manifestation of the metabolic 
syndrome and is currently the most 
common liver disease worldwide, 
affecting one-third of the overall 
population (Erickson, 2009). Hepatic 
steatosis characterized by excess 
hepatic triglyceride (TG) accumulation 
is the hallmark of NAFLD. This simple, 
benign and reversible steatosis can 
progress to irreversible nonalcoholic 




CD36 in mice is characterized by a 
significant reduction of LCFA uptake 
and utilization in heart, skeletal 
muscle, and adipose tissues resulting 
in enhanced plasma free fatty acid (FFA) 
levels (Febbraio et al., 1999) and lipid 
overflow to the liver (Goudriaan et al., 
2003). Indeed, hepatic TG levels are 
increased in CD36 KO mice fed with a 
normal diet (Goudriaan et al., 2003; Hajri 
et al., 2002), in mice fed with a high-fed 
diet (HFD) (Vroegrijk et al., 2013) and in 
the ob/ob-CD36 knock out (KO) mice 
(Nassir et al., 2013). However, reports 
are also controversial, as some studies 
did not report an increase in hepatic 
steatosis in CD36 KO mice fed with a 
normal diet (Clugston et al., 2014) or 
fed with HFD (Cai et al., 2012), or under 
fasting and feeding conditions (Zhou 
et al., 2008). 
One reason for this discrepancy 
could be the type of mice used in the 
aforementioned studies. Some groups 
used CD36 KO mice and their wild type 
(WT) littermates as (Goudriaan et al., 
2003; Hajri et al., 2002) while others 
used C57Bl/6 mice as (Cai et al., 2012; 
Clugston et al., 2014; Vroegrijk et al., 
2013). The choice of a proper control 
group is of vital importance to generate 
scientifically valid and reproducible 
data (Johnson and Besselsen, 2002). 
Therefore, we aimed to clarify the role 
of CD36 in the development of NAFLD 
by subjecting CD36 KO mice to a high-
fed diet for 12 weeks; we included 
both CD36 WT littermates and C57Bl/6 
mice as controls in our study. Our data 
show that CD36 deficiency is indeed 
associated with hepatic steatosis and 
CD36 may thus protect against early 
NAFLD development, but the accuracy 
of these data is dependent on the use 
of proper, WT littermate controls.
Materials and Methods 
Animals and diet intervention
This study was performed with 
the approval of the University of 
Groningen Ethics Committee for Animal 
Experiments, which adheres to the 
principles and guidelines established 
by the European Convention for the 
Protection of Laboratory Animals. Male 
CD36 knockout (CD36 KO) mice and 
their wild type (WT) littermates were 
bred in house and male C57Bl/6J mice 
were purchased from Charles River 
(JAX laboratories, France). Mice were 
individually housed and maintained 
on a 12-hour light/12-hour dark cycle 
with ad libitum access to water and 
standard chow diet (RMH-B; Hope 
Farms, Woerden, NL). Mice aged 14-16 
weeks were subjected to a high-fat diet 
containing 60 kcal% saturated (lard) 
(HFD; D12492, Research Diets, Inc., New 
Brunswick, NJ, USA) for 12 weeks until 
sacrifice at age 26-28 weeks. A subset 
of mice remained on the chow diet 
until age 26-28 weeks.
In vivo VLDL-TG production
CD36 KO and WT mice were injected 
intraperitoneally with Poloxamer 
407 (1g/kg body weight; BASF, 
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Ludwigshaven, Germany;  a kind 
gift of Prof. Uwe Tietge) as a 50 mg/
mL solution in saline as described 
(Gautier et al., 2007). Blood samples 
were drawn by retro-orbital bleeding 
under anesthesia, into heparinized 
tubes at 0, 30, 60, 120, and 240 min after 
injection. Immediately after the final 
blood draw, animals were sacrificed 
under isoflurane anesthesia by cardiac 
puncture. Plasma TG levels and TG 
production rates were determined as 
previously described (Gautier et al., 
2007). Nascent VLDL (d < 1.006) was 
isolated from the final plasma sample 
of each mouse using an Optima TM 
LX tabletop ultracentrifuge (Beckman 
Instruments Inc., Palo Alto, CA, USA) at 
100,000 rpm for 125 minutes. 
Biochemical analysis
Cholesterol and phospholipid (PL) 
concentrations were determined using 
enzymatic kits (TG: Hitachi, Roche, 
Woerden, The Netherlands; cholesterol: 
cholesterol CHOD-PAP, Roche, the 
Netherlands; PL: Diagnostic Systems 
GmbH, Holzheim, Germany) based on 
manufacturer's protocol, respectively. 
Total liver lipids were extracted from 
the liver according to Bligh and Dyer’s 
method (BLIGH and DYER, 1959), 
and were quantified as previously 
reported (Sheedfar et al., 2014b) using 
an enzymatic assay (Tri/GB kit Roche, 
Woerden, The Netherlands). 
Liver histology
Paraffin-embedded sections of 
the liver (4µm) were stained with 
hematoxylin-eosin (H&E), or Oil Red 
O to stain for neutral lipids. Frozen-cut 
liver sections (5 μm) were fixated in 
methanol and stained with antibodies 
against CD68 (AB53443, Abcam, 
Cambridge, UK), and F4/80 (AB6640, 
Abcam, Cambridge, UK) to detect 
activated hepatic macrophages and 
Kupffer cells. Microscopy was performed 
with a Leica DM 3000 microscope with 
a DFC420 camera (Leica Microsystems, 
Rijswijk, The Netherlands). A Leica 
DM 3000 microscope was used for 
photographs. Scoring of steatosis and 
ballooning of hepatocyte degeneration 
and inflammatory foci was done by 
a certified veterinary pathologist 
following a prescribed method (Kleiner 
et al., 2005).
Quantitative real-time PCR— He-
patic gene expression analyses
Quantitative real-time PCR (qRT-PCR) 
was performed in a 7900HT system 
(Applied Biosystems, Warrington, UK) 
using FastStart Universal SYBR Green 
Master (Rox) (Roche, Mannheim, 
Germany). Total RNA from liver and 
visceral adipose tissue (VAT) was isolated 
using QIAazol reagent (QIAGEN, Venlo, 
The Netherlands). First-strand cDNA 
synthesis was performed using the 
Transcriptor Universal cDNA Master Kit 
(Roche, Mannheim, Germany). Primer 
sequences are listed in Supplemental 
Table 1.
Statistics 
Data are presented as mean ± SEM. 
Statistical significance (P < 0.05) was 
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assessed using the non-parametric 
Mann-Whitney test. The software 
used for analysis was GraphPad Prism 
(version 5.00 for Windows, GraphPad 
Software, San Diego, CA, USA).
Results
Mice lacking CD36 are protected 
against HFD-induced weight gain 
In order to address our question 
related to the susceptibility of CD36 KO 
mice to the development of steatosis, 
we challenged mice to a HFD for 12 
weeks. As reported previously (Cai et 
al., 2012; Kennedy et al., 2011), our 
data show that CD36 KO mice are 
protected against body weight gain 
if compared to both WT (Fig. 1A) and 
C57Bl/6 mice (Fig. Sup. 1A). Liver weight 
was significantly reduced in CD36 KO 
mice when compared to WT mice (Fig. 
1B) but it did not differ when compared 
to C57Bl/6 mice (Fig. Sup. 1B). In line 
with this, the liver to body weight ratio 
was unaltered in CD36 KO as compared 
to WT mice (Fig. 1C), suggesting that 
the smaller livers of CD36 KO mice 
were proportional to their reduced 
body weight. As expected, liver to 
body weight ratio did not differ in 
comparison to C57Bl/6 mice (Fig. Sup. 
1C). Moreover, there was no difference 
between CD36 KO and C57Bl/6 mice 
fed with a chow diet on either of these 
parameters (Fig. Sup. 1A-C).
Hepatic steatosis in CD36 KO mice 
is only apparent when WT litter-
mates are used as controls 
We next examined the amount of 
lipid accumulation was significantly 
higher in CD36 KO mice compared to 
WT mice (Fig. 2A). In contrast, the grade 
of steatosis did not differ between CD36 
KO and C57Bl/6 mice fed a HFD for 12 
weeks, as determined by pathological 
assessment of liver sections (Fig. Sup. 
2A-B). Nevertheless, levels were in 
a range of 33% to 66% of steatosis, 
suggesting the occurrence of hepatic 
steatosis in both CD36 KO and C57Bl/6 
mice (Fig. Sup. 2B). Likewise, oil red 
O-stained liver sections (Fig. Sup. 2A) 
and biochemical TG analysis (Fig. Sup. 
Figure 1. CD36 KO mice fed with a HFD are protected against body weight gain. (A) Total body weight 
of WT and CD36 KO mice fed a HFD for 12 weeks were measured. (B) Fasted liver weight and (C) liver weight 
over body weight ratio in WT and CD36 KO mice fed a HFD for 12 weeks. Values are expressed as mean ± 
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2C) confirmed the lack of a difference in 
the level of hepatic steatosis between 
CD36 KO and C57Bl/6 mice. Under 
chow-diet, fat accumulation was not 
observed in either CD36 KO or C57Bl/6 
mice (Fig. Sup. 2A-C). 
Reduced VLDL-TG production 
and secretion in CD36 KO mice as 
compared to WT mice
To assess whether a reduction in 
very-low density lipoprotein (VLDL)-TG 
production and secretion may explain 
Figure 2. Lack of CD36 in mice results in hepatic steatosis and a marked reduction in VLDL produc-
tion and secretion. (A) Liver triglycerides (TG) were assessed biochemically from livers of WT and CD36 KO 
age-matched HF-fed mice. (B) In-vivo very-low density lipoprotein-triglyceride (VLDL-TG) production was 
measured after an intraperitoneal injection with Poloxamer 407. VLDL-TG production rates and (C) Plasma 
VLDL triglyceride levels were determined in HF-fed WT and CD36 KO mice. (D) The composition of VLDL was 
determined as triglycerides (TG), phospholipids (PL) and total cholesterol (TChol) and (E) the diameter of 
VLDL particles in HF-fed WT and CD36 KO mice were calculated. Data are expressed as mean ± SEM, n = 9-10 
per group. *p ≤0.05 (nonparametric Mann-Whitney U test). (Values are expressed as mean ± SEM; n = 10-11 
mice in each group. *p ≤0.05 (nonparametric Mann-Whitney U test). 
the increase in hepatic steatosis in CD36 
KO mice, we subjected CD36 KO and 
WT mice to an intraperitoneal injection 
with Poloxamer-407. We observed that 
hepatic VLDL-TG production (Fig. 2B) 
was significantly reduced in CD36 KO 
mice after this injection. Consistent 
with this, plasma VLDL-TG levels were 
significantly reduced in CD36 KO mice 
as compared to WT mice (Fig. 2C). 
However, plasma VLDL composition 
was not altered (Fig. 2D); it contained a 






































































































































(TChol) and phospholipids (PL) as 
compared to WT mice. In addition, 
the diameter of the VLDL particles did 
not differ between the CD36 and WT 
mice (Fig.3 E), suggesting that not the 
size but the amount of VLDL particles 
exported from the liver is reduced. 
Ablation of CD36 does not con-
tribute to hepatic inflammation in 
CD36 KO mice  
To investigate whether lack of CD36 
may increase the susceptibility to the 
development of diet-induced NASH, 
we determined the expression of the 
macrophage markers Cd68, F4/80, and 
pro-inflammatory cytokines Il1β, Tnf 
in mice fed a HFD for 12 weeks. The 
expression of Cd68, F4/80, Il1β, and 
Tnf (Fig.3 A-D) was not increased in 
livers of CD36 KO mice, suggesting that 
hepatic inflammation was no worse 
in CD36 KO mice as compared to WT 
mice. To the contrary, we observed an 
increased expression of Cd68, Il1β, Il10, 
and Tnf whereas other inflammatory 
related cytokines and genes were 
not increased in CD36 KO mice as 
compared to C57Bl/6 mice (Fig. Sup. 
3A). In addition, pathological scoring 
of the H&E stained liver sections from 
CD36 KO and C57Bl/6 mice revealed 
Figure 3. No sign of hepatic inflammation in CD36 KO mice fed a HFD. mRNA expression of cytokines 
and genes involved in inflammation, and markers of immune cell infiltration including (A) Cluster of Differ-
entiation 68 (Cd68), (B) tumor necrosis factors (Tnf), (C) macrophage maker (F4/80), (D), interleukin-1 β(Il1β), 
and in the liver of WT and CD36 KO mice fed a HFD for 12 weeks. The mRNA expression levels are normalized 
for Cyclophillin A (Ppia). Expression is shown as fold induction compared to WT levels on HF diet. Values are 
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that lobular inflammation (Fig. Sup. 3B) 
and inflammatory foci (Fig. Sup. 3C) are 
not different between CD36 KO and 
C57Bl/6 mice. In addition, immune-
staining of two macrophage markers, 
CD68 and F4/80, confirmed the absence 
of inflammation in CD36 KO mice versus 
C57Bl/6 mice fed with a HFD (Fig. Sup. 
3D-F). Our data therefore suggest that 
lack of CD36 does not contribute to 
hepatic inflammation in CD36 KO mice 
when compared to either WT or C57Bl/6 
mice.
Discussion 
In this study we explored the role of 
CD36 in the development of NAFLD 
in the livers of HFD-fed mice. We 
report that the CD36 deficient mice 
demonstrate an increase in hepatic 
steatosis but only when WT littermate 
mice are taken into account as control 
group. As such, our study may provide 
a rational explanation for the existing 
controversy about CD36 and its role in 
hepatic lipid accumulation. Our data 
also show that CD36 deficiency does 
not aggravate hepatic inflammation 
in mice. This result was independent 
of whether WT or C57Bl/6 mice were 
included as experimental controls. 
CD36 deficiency enhances peripheral 
insulin sensitivity (Hajri et al., 2002). Our 
previous work and that of others has 
pointed to the pathogenic role of CD36 
in diet-induced obesity (Koonen et al., 
2007a) and age-related cardiomyopathy 
and lipotoxicity in heart (Koonen et al., 
2007b, 2010; Sung et al., 2011) and 
skeletal muscle (Koonen et al., 2010; 
Tucker and Turcotte, 2003). Of note, 
studies with CD36 KO mice and CD36 
inhibitors have confirmed a role for 
CD36 in the development of insulin 
resistance and diet-induced obesity 
(Geloen et al., 2012; Koonen et al., 2010; 
Sung et al., 2011; Tucker and Turcotte, 
2003). In addition to this causal role of 
CD36 in obesity-related pathologies, we 
have previously shown that, following 
adenoviral-mediated gene transfer of 
CD36, the latter mediates hepatic LCFA 
uptake and TG accumulation in lean 
mice (Koonen et al., 2007a). Moreover, 
CD36 expression and hepatic lipid 
accumulation are increased by several 
stimuli, including diets rich in fatty 
acids and aging (Koonen et al., 2007a; 
Sheedfar et al., 2014a). Furthermore, 
hepatic CD36 expression is elevated 
in biopsies from patients with non-
alcoholic steatohepatitis(Greco et al., 
2008; Miquilena-Colina et al., 2011; 
Sheedfar et al., 2014a), suggesting that 
CD36 positively correlates with hepatic 
lipid accumulation and NAFLD in both 
mice and humans. However, in our 
study hepatic steatosis is exacerbated 
by CD36 deletion in mice fed a HF-diet 
(Fig. 2A), suggesting that the presence 
of CD36 is beneficial and rather protects 
against the development of NAFLD. 
These results are consistent with a 
previous study showing increased lipid 
accumulation in CD36 KO mice fed a 
HFD (Vroegrijk et al., 2013). However, 
these data do not corroborate the 
current view that CD36 is detrimental 
to hepatic fat uptake. This discrepancy 
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may be explained by the underlying 
mechanisms that contribute to 
steatosis in the liver. Indeed, hepatic 
lipid accumulation in CD36 KO mice is 
commonly believed to originate from 
increased plasma FFA levels as a result of 
a reduced peripheral capacity for LCFA 
uptake and the subsequent overflow 
of lipids to the liver (Goudriaan et al., 
2003). Although in our studies we did 
not measure LCFA uptake, our data 
clearly show that plasma VLDL-TG levels 
were significantly reduced in CD36 KO 
mice as compared to WT mice (Fig. 2C). 
However, plasma VLDL composition 
and the diameter of the VLDL particles 
did not differ between both CD36 and 
WT mice (Fig.2 D-E). This may suggest 
that hepatic steatosis in CD36 KO 
mice is the result of reduced VLDL-TG 
production and secretion (Fig. 2B-C), 
rather than of lipid overflow to the 
livers. This observation concurs with the 
study of Nassir et al. (2013) (Nassir et al., 
2013) in which a reduction in VLDL-TG 
production and secretion was shown 
to contribute to hepatic steatosis in 
ob/ob-CD36 KO mice. However, our 
observation contradicts Goudriaan and 
colleagues, (2005) (Goudriaan et al., 
2005) who showed no change in VLDL-
TG secretion between WT and CD36 KO 
mice. However, the latter study made 
use of anesthesia to quantify VLDL-TG 
secretion in vivo, which may explain 
the discrepancy in study outcomes.
Our data also suggest  that 
CD36 protects from early NAFLD 
development, though at the expense 
of creating dyslipidemia. Indeed, 
while ablation of CD36 is associated 
with intrahepatic lipid accumulation 
(Fig. 2A), the reduction in VLDL-TG 
secretion also attenuates dyslipidemia 
(Fig. 2C). In line with this, postprandial 
hypertriglyceridemia was reduced 
in mice following 21 days of CD36 
inhibition using the small chemical 
molecules AP5055 and AP5258 
(Geloen et al., 2012). Likewise, we have 
previously shown that adenoviral-
mediated overexpression of hepatic 
CD36 leads to dyslipidemia as a direct 
result of increased VLDL-TG production 
following enhanced lipid intake 
(Koonen et al., 2007a). Furthermore, 
CD36 deletion in mice has recently 
been shown to increase prostaglandin 
production by macrophage/Kupffer 
cells. This in turn was shown to 
significantly reduce VLDL secretion by 
neighboring hepatocytes (Nassir et al., 
2013). In line with the recent suggestion 
by Nassir et al. (2013)(Nassir et al., 2013), 
we therefore believe that in addition 
to facilitating hepatic FA flux under 
conditions of fatty acid oversupply 
CD36 may play an additional role in the 
liver. This includes a role as intracellular 
signal transducer to indirectly regulate 
the assembly and secretion of VLDL 
particles via phospholipid deacylation 
and eicosanoid production (Nassir et 
al., 2013). It remains to be determined 
whether the influence of CD36 on 
VLDL secretion is more significant 
than its effect on hepatic FA uptake. 
This is of particular interest, due to the 
promising potential of CD36 to reduce 
postprandial hypertriglyceridemia and 
protect against diabetic dyslipidemia.
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Using WT littermate and C57Bl/6 
mice as controls in our study, we have 
shown that the type of mice used as 
experimental controls can explain some 
of the discrepancies in data related to 
lipid accumulation in CD36 KO mice. 
Indeed, CD36 KO mice did exhibit 
hepatic steatosis when compared 
to WT littermate mice (Fig. 2A). This 
confirms previous findings in which 
CD36 ablation led to accumulation 
of hepatic lipids after injection with 
[3H]FFA bolus, which was not the case 
with WT littermate mice (Goudriaan 
et al., 2003). In addition, we did not 
observe an increment in hepatic TG 
levels in CD36 KO mice fed with HFD 
compared to C57BL/6 mice (Fig. Sup. 2). 
This was in line with previous findings 
from (Cai et al., 2012). They reported 
no effect of CD36 ablation on hepatic 
lipid accumulation in KO mice when 
compared to C57BL/6 mice fed a similar 
HF-diet (60 kcal% saturated lard fat) 
as in our study. However, in addition 
to the background of the mice, we 
must consider the stimulatory effect 
of fasting and the animal age on 
hepatic TG levels (Kersten et al., 1999; 
Sheedfar et al., 2013), as these factors 
may also play a role in the discrepancies 
between hepatic TG levels in CD36 KO 
mice reported in the various studies 
(Clugston et al., 2014; Goudriaan et 
al., 2003, 2005; Hajri et al., 2002; Zhou 
et al., 2008).
Targeted deletion of CD36 in mice 
has been shown to reduce macrophage 
content and levels of pro-inflammatory 
cytokines in the plasma (Kuchibhotla et 
al., 2008; Moore et al., 2005; Rahaman 
et al., 2006; Stewart et al., 2010; Stuart 
et al., 2005a). Moreover, CD36 has been 
shown to facilitate Toll-like receptor 
(TLR) signaling and to activate the 
innate host response, in the presence 
of ox-LDL via TLR4/TLR6 and in 
response to diacylglyceride via TLR2/6 
(Hoebe et al., 2005; Rahaman et al., 
2006; Stewart et al., 2010; Stuart et al., 
2005b; Triantafilou et al., 2006). As a 
result, CD36 has been implicated in the 
systemic inflammation associated with 
chronic diseases. In addition, Bieghs et 
al have shown that CD36 aggravates 
NASH in the LDL receptor KO mice 
model (due to the accumulation of 
oxidized lipids) (Bieghs et al., 2010). 
Although we did not observe a role for 
CD36 in the development of hepatic 
inflammation (Fig 3, Sup. 3), it may be 
that under high fat conditions these 
oxidized lipids do not accumulate to 
the same extent and thus do not play 
a dramatic role in inflammation via this 
mechanism. Since CD36 has recently 
been shown to contribute to adipose 
tissue inflammation and macrophage 
infiltration (Cai et al., 2012; Kennedy et 
al., 2011), the lack of effect on hepatic 
inflammation in our data may thus 
suggest the existence of a tissue-
specific role for CD36 in the control 
of the chronic systemic inflammatory 
response, a role which needs further 
investigation.
In summary, the results presented 
here show that CD36 plays an important 
role in the maintenance of hepatic lipid 
homeostasis in a genetic and dietary 
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mouse model of NAFLD. Our findings 
demonstrate that lack of CD36 results 
in hepatic TG accumulation mediated 
by a reduction in VLDL-TG production 
and secretion. Despite this increase in 
hepatic steatosis, hepatic inflammation 
did not occur in CD36 KO mice fed a 
HF-diet. Thus, while lack of CD36 is 
associated with protection against 
adipose tissue inflammation (Cai et 
al., 2012), it does not similarly affect 
inflammation in the livers of CD36 KO 
mice. Our study thus describes the 
novel finding that CD36 has a tissue 
specific role in the control of metabolic 
inflammation in mice. Yet, the use of 
liver-specific CD36 deletion and over-
expression models will enhance current 
understanding of the role of CD36 
in lipid metabolism and metabolic 
inflammation in the liver.
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Supplemental Table 1. Primer sequences used for RT-PCR.
 Gene Forward primer 5’-3’ Reverse primer 5’-3’
 F4/80 TGTGTCGTGCTGTTCAGAACC AGGAATCCCGCAATGATGG
 Cd68 TGACCTGCTCTCTCTAAGGCTACA TCACGGTTGCAAGAGAAACATG
 Cd11b  TCAGAGAATGTCCTCAGCAG TGAGACAAACTCCTTCATCTTC
 Il1β TGCAGCTGGAGAGTGTGG TGCTTGTGAGGTGCTGATG
 Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG
 A20 GCTCTGAAAACCAATGGTGATG CCGAGTGTCTGTCTCCTTAAG
 Mrc1 TTTGGAATCAAGGGCACAGAG TGCTCCACAATCCCGAACC
 TNF GTAGCCCACGTCGTAGCAAAC AGTTGGTTGTCTTTGAGATCCATG
 Col1α AACCCTGCCCGCACATG  CAGACGGCTGAGTAGGGAACA
 Mmp9 CCTGGAACTCACACGACATCTTC    TGGAAACTCACACGCCAGAA
 Ppia TTCCTCCTTTCACAGAATTATTCCA CCGCCAGTGCCATTATGG
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Supplemental Figure 1. No alterations in body and liver weight were observed between C57Bl/6 mice 
and CD36 KO mice fed a normal diet. CD36 KO mice fed a HFD are protected from body weight gain. 
(A) Total body weight of C57Bl/6 and CD36 KO mice fed a chow diet and HFD were measured. Fasted liver 
weight and (C) liver weight over percentage of body weight in WT and CD36 KO mice fed a HFD were mea-





Supplemental Figure 2. No alterations observed in CD36 KO mice in hepatic steatosis development. (A) Representative 
pictures of H&E of liver sections, from livers of C57Bl/6 and CD36 KO age-matched chow diet and HF-fed mice. Oil Red O 
(ORO) staining was performed only in HFD group. (B) Steatosis (microvesicular and macrovesicular) grade 0 < 5%; 1=5-33%; 
2= 33-66%; 3= > 66% grade were pathologically scored. (C) Liver triglycerides (TG) were assessed biochemically. (Values are 
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Supplemental Figure 3. Hepatic inflammation is non-significantly increased in CD36 KO mice fed a HFD when compared 
to C57Bl/6 mice. (A) mRNA expression of cytokines and genes involved in inflammation and markers of immune cell infiltration 
including Cluster of Differentiation 68 (Cd68), macrophage maker (F4/80), cluster of differentiation molecule 11b (Cd11b), 
interleukin-1β (Il1β), interleukin-10 (Il10), ubiquitin-modifying enzyme (A20), Macrophage mannose receptor 1 (Mrc-1), 
tumor necrosis factors (Tnf), collagen type I alpha (Col1a), matrix metallopeptidase 9 (mmp9) in the liver of WT and CD36 KO 
mice fed a HFD for 12 weeks. The mRNA expression levels are normalized for Cyclophillin A (Ppia). (B) Pathological scoring 
of lobular inflammation and (C) inflammatory foci per 5 random fields in 200x magnification. (D) Representative pictures of 
immunohistochemical stainings of Cd68 and F4/80 on liver sections, (E) quantification of Cd68 and (F) F4/80 staining in the 
livers of C57Bl/6 and CD36 KO mice fed a HFD for 12 weeks. Expression is shown as fold induction compared to C57Bl/6 mice 
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